Deciphex Secures €15 Million Investment from Claret Capital Partners to Fuel U.S. Expansion and Growth in Histopathology Services

"Deciphex has secured a €15 million investment from Claret Capital Partners to support its expansion in the U.S. and its goal of becoming the leading histopathology reporting service provider in the UK by 2027. The funding will help Deciphex enhance its AI-powered digital pathology solutions to improve patient outcomes. Claret Capital Partners, Europe's largest independent growth debt fund manager, has been impressed with Deciphex's execution in meeting market demands since their partnership began in 2023."

Flynn O'Driscoll advised Deciphex in a €15 million investment transaction with Claret Capital Partners, Europe's largest independent growth debt fund manager. This strategic financing will facilitate Deciphex's expansion in the United States and support its goal of becoming the leading provider of histopathology reporting services in the UK by 2027. Donal O'Shea, Founder and CEO of Deciphex, expressed that this extended relationship with Claret Capital Partners provides the necessary capital to execute their ambitious growth plans. Joey Mason, Venture Partner at Claret Capital Partners, highlighted their satisfaction in supporting Deciphex with follow-on funding, noting the impressive execution skills of the Deciphex team in meeting the growing market demand for their solutions. The legal team from Flynn O'Driscoll that advised Deciphex included Gavin Lawlor, Daniel Hackett, Grace Connolly Gusmões, Orlagh Scollard, Michael Hanley, Danny Heffernan, and Senan Ross, all of whom are part of the Corporate and Banking teams. The press release does not specify their seniority or practice areas beyond their team affiliations.

Deciphex Secures €15 Million Investment from Claret Capital Partners to Fuel U.S. Expansion and Growth in Histopathology Services

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads